Cantor Fitzgerald assumed coverage on shares of OptiNose (NASDAQ:OPTN) in a report published on Tuesday, reports. The brokerage issued an overweight rating and a $30.00 price target on the stock.

“: We are initiating research coverage of OPTN stock with an Overweight rating and 12-month PT of $30. We view Xhance as an asset that will create significant share value and allow the company to expand commercial activities into ENT- and allergist-managed medical conditions. We believe OPTN should be able to leverage the proprietary exhalation delivery system (EDS) to develop therapies that fit within the target physician population and could be applicable for other medical uses that could create partnering/out-licensing opportunities.”,” the firm’s analyst wrote.

Other analysts have also issued research reports about the company. Zacks Investment Research raised OptiNose from a hold rating to a buy rating and set a $30.00 price target for the company in a research note on Wednesday, July 18th. Piper Jaffray Companies reaffirmed a buy rating and issued a $34.00 price target on shares of OptiNose in a research note on Wednesday, July 18th. Finally, ValuEngine raised OptiNose from a sell rating to a hold rating in a research note on Wednesday, May 2nd. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. OptiNose presently has a consensus rating of Buy and a consensus price target of $30.50.

OPTN stock traded down $0.35 on Tuesday, reaching $21.57. The company’s stock had a trading volume of 600 shares, compared to its average volume of 211,219. OptiNose has a 12-month low of $15.01 and a 12-month high of $30.00. The firm has a market capitalization of $812.58 million and a price-to-earnings ratio of -3.93. The company has a quick ratio of 9.50, a current ratio of 9.66 and a debt-to-equity ratio of 0.57.

OptiNose (NASDAQ:OPTN) last announced its quarterly earnings results on Monday, May 14th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.07). The company had revenue of $0.87 million during the quarter. equities research analysts anticipate that OptiNose will post -3.15 earnings per share for the current year.

In other OptiNose news, Director Robert P. O’neil purchased 2,000 shares of the company’s stock in a transaction that occurred on Friday, June 8th. The stock was bought at an average price of $22.75 per share, with a total value of $45,500.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Sriram Venkataraman sold 2,875,000 shares of the firm’s stock in a transaction on Monday, June 11th. The stock was sold at an average price of $20.92, for a total value of $60,145,000.00. The disclosure for this sale can be found here. Company insiders own 67.80% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the business. American Century Companies Inc. raised its holdings in OptiNose by 16.7% in the first quarter. American Century Companies Inc. now owns 107,732 shares of the company’s stock worth $2,157,000 after purchasing an additional 15,415 shares in the last quarter. BlackRock Inc. bought a new position in OptiNose in the fourth quarter worth $4,351,000. Deutsche Bank AG bought a new position in OptiNose in the fourth quarter worth $247,000. Geode Capital Management LLC bought a new position in OptiNose in the fourth quarter worth $1,356,000. Finally, California State Teachers Retirement System bought a new position in OptiNose in the fourth quarter worth $162,000. Institutional investors and hedge funds own 29.06% of the company’s stock.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Read More: Closed-End Mutual Funds

Analyst Recommendations for OptiNose (NASDAQ:OPTN)

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with's FREE daily email newsletter.